Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33150513" target="_blank" >RIV/61989592:15110/14:33150513 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.2217/IMT.14.50" target="_blank" >http://dx.doi.org/10.2217/IMT.14.50</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2217/IMT.14.50" target="_blank" >10.2217/IMT.14.50</a>

Result language

angličtina

Original language name

Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer

Original language description

Tumors in about 15% of patients with breast cancer overexpress HER2. Trastuzumab (Herceptin (R); F. Hoffmann-La Roche, Basel, Switzerland) is a humanized monoclonal antibody against HER2. While the introduction of trastuzumab has changed the natural course of HER2-positive breast cancer, the need for repeated administration of the drug over a prolonged period of time represents a challenge. Similarly to other chronic disorders, subcutaneous administration of monoclonal antibodies may be of advantage inthis setting. The results of a prospective randomized Phase III study have demonstrated that subcutaneous trastuzumab is noninferior compared with the intravenous administration of the drug in terms of efficacy (assessed as pathological complete responserate) as well as in pharmacokinetic parameters. Moreover, another prospective randomized study showed that an overwhelming majority of patients prefer subcutaneous over intravenous trastuzumab. The advent of subcutaneous trastuzumab repr

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NT13564" target="_blank" >NT13564: Predictive factors of pathologic response to neoadjuvant chemotherapy in patients with HER-2 positive or triple negative breast carcinoma</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Immunoterapy

ISSN

1750-743X

e-ISSN

—

Volume of the periodical

6

Issue of the periodical within the volume

7

Country of publishing house

GB - UNITED KINGDOM

Number of pages

9

Pages from-to

811-819

UT code for WoS article

—

EID of the result in the Scopus database

—